~~<i id='A25AC83E69'><strike id='A25AC83E69'><tt id='A25AC83E69'><pre id='A25AC83E69'></pre></tt></strike></i>~~

Home» knowledge» focus

focus

author：knowledge 2025-09-29 07:44:01 Page View：4

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virtual repurposing can help discover new uses for existing drugs
Next article： FDA approval of Sarepta Duchenne genetic therapy gives me hope

explore

Activists slam private health insurers over coverage restrictions

ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

Elisabeth Bik tackles the widespread issue of research misconduct

AlexHogan/STATElisabethBik,amicrobiologistbytraining,hasbecomeoneoftheworld’smostinfluentialscienced

Apple is now the first public company to be valued at $3 trillion

6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

Using force crossed my mind when examining a defiant young patient

Inthis1895photo,nursesanddoctorsinoculateachildwithdiphtheriaantitoxinatthePasteurInstituteinNewYork